FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 625 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Happy 29th Birthday OncoLink! March 7, 2023 Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... July 19, 2024 Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 Load more HOT NEWS BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... COVID-19 vaccine and cancer – latest updates Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate...
